Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • motor neuron disease

    - PMLiVE

    Lancet Commission report identifies two new modifiable dementia risk factors

    The new risk factors identified are untreated vision loss and high low-density lipoprotein

    - PMLiVE

    Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

    The company is seeking approval of donanemab to treat patients with early stages of the disease

    - PMLiVE

    LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

    The rare neurodegenerative disease affects one in every 300 people in the UK

    - PMLiVE

    Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

    Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

    - PMLiVE

    Study suggests hearing aids could prevent onset and progression of dementia

    People with severe hearing loss had an increased risk of up to 20% of developing dementia

    - PMLiVE

    LifeArc launches £5m motor neurone disease drug repurposing programme

    Research teams will be eligible to receive up to £750,000 per project through the programme

    - PMLiVE

    New UK research institute launched for motor neurone disease

    The research institute will bring together MND labs, clinical centres and researchers

    - PMLiVE

    New blood test could one day be used to diagnose Parkinson’s disease

    The discovery could potentially lead to the development of a definitive diagnostic test

    - PMLiVE

    LSTM and LifeArc announce partnership and research fund to tackle infectious diseases

    The research responds to a need for new treatments and diagnostic technologies

    - PMLiVE

    LifeArc launches rare disease programme with £100m investment

    An initial £40m will go towards the creation of up to five rare disease research centres

    - PMLiVE

    LifeArc partners with UK Dementia Research Institute

    Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

    - PMLiVE

    LifeArc creates £10m COVID-19 research fund

    Medical research charity joins efforts against coronavirus

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links